|
1
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wcislo G and Szczylik C: Foreword. Ovarian
cancer-pathobiology, diagnosis and overview of contemporary methods
of treatment. Termedia; Poznan: pp. 9–10. 2010
|
|
3
|
Urban A and Miszczyk L: Ovarian
cancer-diagnostical and therapeutical dilema in oncological
gynecology. Wspolczesna Onkol. 7:294–300. 2003.In Polish.
|
|
4
|
Gancz D and Fishelson Z: Cancer resistance
to complement-dependent cytotoxicity (CDC): Problem-oriented
research and development. Mol Immunol. 46:2794–2800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sarma JV and Ward PA: The complement
system. Cell Tissue Res. 343:227–235. 2011. View Article : Google Scholar :
|
|
6
|
Fishelson Z, Donin N, Zell S, Schultz S
and Kirschfink M: Obstacles to cancer immunotherapy: Expression of
membrane complement regulatory proteins (mCRPs) in tumors. Mol
Immunol. 40:109–123. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu B, Nash J, Runowicz C, Swede H,
Stevens R and Li Z: Ovarian cancer immunotherapy: Opportunities,
progresses and challenges. J Hemato Oncol. 3(7)2010. View Article : Google Scholar
|
|
8
|
Junnikkala S, Hakulinen J, Jarva H,
Manuelian T, Bjørge L, Bützow R, Zipfel PF and Meri S: Secretion of
soluble complement inhibitors factor H and factor H-like protein 1
(FHL-1) by ovarian tumor cells. Br J Cancer. 87:1119–1127. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rodriguez de Cordoba S, Esparza-Gordillo
J, Goicoechea de Jorge E, Lopez-Trascasa M and Sánchez-Corral P:
The human complement factor H: Functional roles, genetic variations
and disease associations. Mol Immunol. 41:355–367. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kryczek I, Gryboś M and Lange A:
Biological and clinical impact of IL-6 production by ovarian
carcinoma cells. Wspolczesna Onkol. 3:195–198. 1999.In Polish.
|
|
11
|
Nowak M, Głowacka E, Szpakowski M, Szyllo
K, Malinowski A, Kulig A, Tchórzewski H and Wilczyński J:
Proinflamatory and immunosupresive serum, ascites and cyst fluid
cytokines in patients with early and advenced ovarian cancer and
benign ovarian tumors. Neuro Endocrinol Lett. 31:375–383. 2010.
|
|
12
|
Chou CH, Wei LH, Kuo ML, Huang YJ, Lai KP,
Chen CA and Hsieh CY: Up-regulation of interleukin-6 in human
ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by
lysophosphatidic acid, an ovarian cancer-activating factor.
Cancerogenesis. 26:45–52. 2005. View Article : Google Scholar
|
|
13
|
Dijkgraaf EM, Welters MJ, Nortier JW, van
der Burg SH and Kroep JR: Interleukin-6/interleukin-6 receptor
pathway as a new therapy target in epithelial ovarian cancer. Curr
Pharm Des. 18:3816–3827. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dobrzycka B, Mackowiak-Matejczyk B,
Terlikowska KM, Kulesza-Bronczyk B, Kinalski M and Terlikowski SJ:
Serum levels of IL-6, IL-8 and CRP as prognostic factors in
epithelial ovarian cancer. Eur Cytokine Netw. 24:106–113.
2013.PubMed/NCBI
|
|
15
|
Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ
and Li LZ: Autocrine production of interleukin-6 confers cisplatin
and paclitaxel resistance in ovarian cancer cells. Cancer Lett.
295:110–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spiller OB, Criado-García O, Rodríguez De
Córdoba S and Morgan BP: Cytokine-mediated up-regulation of CD55
and CD59 protects human hepatoma cells from cells from complement
attack. Clin Exp Immunol. 121:234–241. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
18
|
Ajona D, Castaño Z, Garayoa M, Zudaire E,
Pajares MJ, Martinez A, Cuttitta F, Montuenga LM and Pio R:
Expression of complement factor H by lung cancer cells: Effects on
the activation of the alternative pathway of complement. Cancer
Res. 64:6310–6318. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bjørge L, Hakulinen J, Vintermy OK, Jarva
H, Jensen TS, Iversen OE and Meri S: Ascitic complement system in
ovarian cancer. Br J Cancer. 92:895–905. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W
and Yao Z: Regulatory effect of E2, IL-6 and IL-8 on the Growth of
epithelial ovarian cancer cells. Cell Mol Immunol. 2:365–372.
2005.PubMed/NCBI
|
|
21
|
Józsi M and Zipfel PF: Factor H family
proteins and human diseases. Trends Immunol. 29:380–387. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kapka-Skrzypczak L, Wolinska E, Szparecki
G, Wilczynski GM, Czajka M and Skrzypczak M: CD55, CD59, factor H
and factor H-like 1 gene expression analysis in tumors of the ovary
and corpus uteri origin. Immunol Lett. 167:67–71. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thibault B, Castells M, Delord JP and
Couderc B: Ovarian cancer microenvironment: Implications for cancer
dissemination and chemoresistance acquisition. Cancer Metastasis
Rev. 33:17–39. 2014. View Article : Google Scholar
|
|
24
|
Józsi M, Manuelian T, Heinen S, Oppermann
M and Zipfel PF: Attachment of the soluble complement regulator
factor H to cell and tissue surfaces: Relevance for pathology.
Histol Histopathol. 19:251–258. 2004.PubMed/NCBI
|
|
25
|
Kopp A, Hebecker M, Svobodová E, Józsi M
and Factor H: A complement regulator in health and disease, and a
mediator of cellular interactions. Biomolecules. 2:46–75. 2012.
View Article : Google Scholar : PubMed/NCBI
|
